NCT04901806: Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NTRK, EWSR1-WT1+
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have progressed on at least one systemic therapy regimen administered for advanced or metastatic disease; Breast cancer patients are eligible for phase 1 of the study; Breast cancer patients are only eligible for phase 2 of the study if they have previously received treatment with a TRK inhibitor & have a documented resistance mutation(s) (e.g., solvent front, gatekeeper or xDFG mutation)

Up ↑